Lantheus (NASDAQ:LNTH) Trading Down 4.6% – Should You Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price was down 4.6% during trading on Wednesday . The company traded as low as $100.01 and last traded at $99.85. Approximately 106,252 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 927,199 shares. The stock had previously closed at $104.62.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of research reports. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Stock Performance

The company has a market capitalization of $6.81 billion, a P/E ratio of 16.52 and a beta of 0.38. The firm’s fifty day moving average is $91.43 and its 200-day moving average is $96.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus in the third quarter valued at about $25,000. Kestra Investment Management LLC purchased a new stake in Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus in the fourth quarter worth $37,000. UMB Bank n.a. increased its stake in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC purchased a new stake in shares of Lantheus in the third quarter worth $60,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.